These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 34648813)
1. Functional evaluation of vandetanib metabolism by CYP3A4 variants and potential drug interactions in vitro. Han M; Zhang X; Ye Z; Wang J; Qian J; Hu G; Cai J Chem Biol Interact; 2021 Dec; 350():109700. PubMed ID: 34648813 [TBL] [Abstract][Full Text] [Related]
2. Functional assessment of the effects of CYP3A4 variants on acalabrutinib metabolism in vitro. Han M; Qian J; Ye Z; Xu R; Chen D; Xie S; Cai J; Hu G Chem Biol Interact; 2021 Aug; 345():109559. PubMed ID: 34153224 [TBL] [Abstract][Full Text] [Related]
3. Characterization of Genetic Variation in CYP3A4 on the Metabolism of Cabozantinib in Vitro. Lin QM; Li YH; Lu XR; Wang R; Pang NH; Xu RA; Cai JP; Hu GX Chem Res Toxicol; 2019 Aug; 32(8):1583-1590. PubMed ID: 31293154 [TBL] [Abstract][Full Text] [Related]
4. Functional characterization of 27 CYP3A4 protein variants to metabolize regorafenib in vitro. Li YH; Lin QM; Pang NH; Zhang XD; Huang HL; Cai JP; Hu GX Basic Clin Pharmacol Toxicol; 2019 Oct; 125(4):337-344. PubMed ID: 31058459 [TBL] [Abstract][Full Text] [Related]
5. Functional Measurement of CYP2C9 and CYP3A4 Allelic Polymorphism on Sildenafil Metabolism. Tang PF; Zheng X; Hu XX; Yang CC; Chen Z; Qian JC; Cai JP; Hu GX Drug Des Devel Ther; 2020; 14():5129-5141. PubMed ID: 33262574 [TBL] [Abstract][Full Text] [Related]
6. Marsdenia tenacissima extract inhibits gefitinib metabolism in vitro by interfering with human hepatic CYP3A4 and CYP2D6 enzymes. Han SY; Zhao HY; Zhou N; Zhou F; Li PP J Ethnopharmacol; 2014; 151(1):210-7. PubMed ID: 24157377 [TBL] [Abstract][Full Text] [Related]
7. Identification of Human Enzymes Oxidizing the Anti-Thyroid-Cancer Drug Vandetanib and Explanation of the High Efficiency of Cytochrome P450 3A4 in its Oxidation. Indra R; Pompach P; Martínek V; Takácsová P; Vavrová K; Heger Z; Adam V; Eckschlager T; Kopečková K; Arlt VM; Stiborová M Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31295928 [TBL] [Abstract][Full Text] [Related]
8. Use of transgenic mouse models to understand the oral disposition and drug-drug interaction potential of cobimetinib, a MEK inhibitor. Choo EF; Woolsey S; DeMent K; Ly J; Messick K; Qin A; Takahashi R Drug Metab Dispos; 2015 Jun; 43(6):864-9. PubMed ID: 25813936 [TBL] [Abstract][Full Text] [Related]
9. Utility of CYP3A4 and PXR-CAR-CYP3A4/3A7 Transgenic Mouse Models To Assess the Magnitude of CYP3A4 Mediated Drug-Drug Interactions. Ly JQ; Messick K; Qin A; Takahashi RH; Choo EF Mol Pharm; 2017 May; 14(5):1754-1759. PubMed ID: 28345929 [TBL] [Abstract][Full Text] [Related]
10. Effect of recombinant CYP3A4 variants and interaction on imatinib metabolism in vitro. Chen J; Hu Y; Hu J; Ye Z; Lin Q; Cai JP; Hu GX; Xu RA Biomed Pharmacother; 2024 Nov; 180():117511. PubMed ID: 39366029 [TBL] [Abstract][Full Text] [Related]
11. Functional assessment of Fang P; Tang PF; Xu RA; Zheng X; Wen J; Bao SS; Cai JP; Hu GX Drug Des Devel Ther; 2017; 11():3503-3510. PubMed ID: 29263648 [TBL] [Abstract][Full Text] [Related]
12. Functional Characterization of 22 CYP3A4 Protein Variants to Metabolize Ibrutinib In Vitro. Xu RA; Wen J; Tang P; Wang C; Xie S; Zhang BW; Zhou Q; Cai JP; Hu GX Basic Clin Pharmacol Toxicol; 2018 Apr; 122(4):383-387. PubMed ID: 29117640 [TBL] [Abstract][Full Text] [Related]
13. Functional assessment of CYP3A4 and CYP2C19 genetic polymorphisms on the metabolism of clothianidin invitro. Hu Y; Ye Z; Wu H; Chen X; Xia H; Cai JP; Hu GX; Xu RA Chem Biol Interact; 2024 Aug; 399():111154. PubMed ID: 39025286 [TBL] [Abstract][Full Text] [Related]
14. Effects of Clarithromycin and Ketoconazole on FK506 Metabolism in Different CYP3A4 Genotype Recombinant Metabolic Enzyme Systems. Wen J; Xiao Y; Zhao M; Yang C; Hu W Curr Drug Metab; 2024; 25(2):174-177. PubMed ID: 38523538 [TBL] [Abstract][Full Text] [Related]
15. Inhibition and stimulation of intestinal and hepatic CYP3A activity: studies in humanized CYP3A4 transgenic mice using triazolam. van Waterschoot RA; Rooswinkel RW; Sparidans RW; van Herwaarden AE; Beijnen JH; Schinkel AH Drug Metab Dispos; 2009 Dec; 37(12):2305-13. PubMed ID: 19752211 [TBL] [Abstract][Full Text] [Related]
16. Effects of ketoconazole or rifampin on the pharmacokinetics of tivozanib hydrochloride, a vascular endothelial growth factor receptor tyrosine kinase inhibitor. Cotreau MM; Siebers NM; Miller J; Strahs AL; Slichenmyer W Clin Pharmacol Drug Dev; 2015 Mar; 4(2):137-42. PubMed ID: 27128217 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of Recombinant CYP3A4 Variants on the Metabolism of Oxycodone In Vitro. Cai Y; Lin Q; Jin Z; Xia F; Ye Y; Xia Y; Papadimos TJ; Wang Q; Hu G; Cai J; Chen L Chem Res Toxicol; 2021 Jan; 34(1):103-109. PubMed ID: 33393779 [TBL] [Abstract][Full Text] [Related]
18. Effects of 27 CYP3A4 protein variants on saxagliptin metabolism in vitro. Liu Q; Ou-Yang QG; Lin QM; Lu XR; Ma YQ; Li YH; Xu RA; Lin DD; Hu GX; Cai JP Fundam Clin Pharmacol; 2022 Feb; 36(1):150-159. PubMed ID: 33961299 [TBL] [Abstract][Full Text] [Related]
19. Genetic variations of CYP3A4 on the metabolism of itraconazole in vitro. Xie SL; Zhu X; Gao N; Lin Q; Chen C; Yang YJ; Cai JP; Hu GX; Xu RA Food Chem Toxicol; 2023 Nov; 181():114101. PubMed ID: 37863381 [TBL] [Abstract][Full Text] [Related]
20. Gene Polymorphisms and Drug-Drug Interactions Determine the Metabolic Profile of Blonanserin. Ye F; Li X; Ni J; Xu X; Luo J; Zhong Y; Wang Y; Wang S; Zhang Y; Hu G; Qian J J Pharmacol Exp Ther; 2024 Jan; 388(1):190-200. PubMed ID: 37863485 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]